Traumatic Optic Neuropathy Treatment Trial 2 — TONTT-2

Traumatic Optic Neuropathy Clinical Trial

Official title:
Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT

Status Completed

Clinical Trial Summary

After introducing intravenous erythropoietin (EPO) as an option for treatment of patients with indirect traumatic optic neuropathy in 2011 and publishing non inferiority trial in Oct.2017), TONTT2 is aiming to find out the best dose and timing of EPO administration in this group of patients.

Clinical Trial Description

Patients with TON will be visited. After being eligible to enter the study and obtaining informed consent, they will be randomly assigned into 3 groups of different total dose of intravenous administration of EPO to which patients and outcome assessors will be masked. They will be assessed at different follow up time periods with the last follow up of at least 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03308448
Study type	Interventional
Source	Iran University of Medical Sciences
Contact
Status	Completed
Phase	Phase 3
Start date	January 6, 2018
Completion date	March 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06168188` - The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy	Early Phase 1
Recruiting	`NCT02711982` - Surgery for Traumatic Optic Neuropathy	N/A
Recruiting	`NCT05140486` - Targeted Shortwave Diathermy Combined With Perceptual Training for Patients With Severe Traumatic Optic Neuropathy	N/A
Recruiting	`NCT05353413` - Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.	N/A
Completed	`NCT01783847` - Traumatic Optic Neuropathy Treatment Trial (TONTT)	Phase 1/Phase 2
Recruiting	`NCT05147701` - Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases	Phase 1